{"DataElement":{"publicId":"5079227","version":"1","preferredName":"Intravenous Immunoglobulin Therapy Reason","preferredDefinition":"An explanation that describes the reason for intravenous immunoglobulin therapy.","longName":"5078794v1.0:5116272v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"5078794","version":"1","preferredName":"Intravenous Immunoglobulin Therapy Reason","preferredDefinition":"The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections._An explanation of the cause of some phenomenon or action.","longName":"5077931v1.0:2390595v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"5077931","version":"1","preferredName":"Intravenous Immunoglobulin Therapy","preferredDefinition":"The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections.","longName":"C121331","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Immunoglobulin Therapy","conceptCode":"C121331","definition":"The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2668299A-2A50-75DC-E050-BB89AD433175","latestVersionIndicator":"Yes","beginDate":"2015-12-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-08","modifiedBy":"ONEDATA","dateModified":"2015-12-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2390595","version":"1","preferredName":"Reason","preferredDefinition":"An explanation of the cause of some phenomenon or action.","longName":"C25638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE52ECB4-C378-617F-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-16","modifiedBy":"ONEDATA","dateModified":"2005-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"26684B2C-5185-B4BC-E050-BB89AD434E9B","latestVersionIndicator":"Yes","beginDate":"2015-12-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-08","modifiedBy":"NYCHM","dateModified":"2017-01-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5116272","version":"1","preferredName":"Intravenous Immunoglobulin Therapy Reason","preferredDefinition":"The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections._An explanation of the cause of some phenomenon or action.","longName":"5116272v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Prophylaxis for low IgG with no active infection","valueDescription":"Preventive Intervention Low IgG Negation Infectious Disorder","ValueMeaning":{"publicId":"5116274","version":"1","preferredName":"Preventive Intervention Low IgG Negation Infectious Disorder","longName":"5116274","preferredDefinition":"In medicine, action taken to decrease the chance of getting a disease or condition. For example, cancer prevention includes avoiding risk factors (such as smoking, obesity, lack of exercise, and radiation exposure) and increasing protective factors (such as getting regular physical activity, staying at a healthy weight, and having a healthy diet).: A minimum level or position or degree; less than normal in degree, intensity or amount.: An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.: An operation in which a term denies or inverts the meaning of another term or construction.: A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Preventive Intervention","conceptCode":"C15843","definition":"Therapeutic, nutritional, environmental, social and/or behavioral interventions at the societal, community, organizational or individual levels to reduce, modify or stop the course of a disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Low","conceptCode":"C54722","definition":"A minimum level or position or degree; less than normal in degree, intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"IgG","conceptCode":"C568","definition":"An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Infectious Disorder","conceptCode":"C26726","definition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2AB6F752-7818-C33D-E050-BB89AD432626","latestVersionIndicator":"Yes","beginDate":"2016-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2AB6F752-7831-C33D-E050-BB89AD432626","beginDate":"2016-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-01","modifiedBy":"ONEDATA","dateModified":"2016-02-01","deletedIndicator":"No"},{"value":"Active infection with normal IgG","valueDescription":"Infectious Disorder Normal IgG","ValueMeaning":{"publicId":"5116273","version":"1","preferredName":"Infectious Disorder Normal IgG","longName":"5116273","preferredDefinition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.: Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.: An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infectious Disorder","conceptCode":"C26726","definition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Normal","conceptCode":"C14165","definition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"IgG","conceptCode":"C568","definition":"An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2AB6F752-77EF-C33D-E050-BB89AD432626","latestVersionIndicator":"Yes","beginDate":"2016-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2AB6F752-7808-C33D-E050-BB89AD432626","beginDate":"2016-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-01","modifiedBy":"ONEDATA","dateModified":"2016-02-01","deletedIndicator":"No"},{"value":"Other indication","valueDescription":"Other Indication","ValueMeaning":{"publicId":"3158657","version":"1","preferredName":"Other Indication","longName":"3158657","preferredDefinition":"Different than the one(s) previously specified or mentioned.: A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indication","conceptCode":"C41184","definition":"A sign, signal, circumstance, or symptom which serves to indicate or point out the cause, pathology, treatment, or issue of an attack of disease; the basis for initiation of a treatment for a disease or of a diagnostic test (causal, or symptomatic, or disease-specific indication).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"94C8A52B-3A15-273E-E040-BB89AD435839","latestVersionIndicator":"Yes","beginDate":"2010-11-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2010-11-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2AB6F752-783D-C33D-E050-BB89AD432626","beginDate":"2016-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-01","modifiedBy":"ONEDATA","dateModified":"2016-02-01","deletedIndicator":"No"},{"value":"Active infection in the setting of low IgG","valueDescription":"Infectious Disorder Low IgG","ValueMeaning":{"publicId":"5116275","version":"1","preferredName":"Infectious Disorder Low IgG","longName":"5116275","preferredDefinition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.: A minimum level or position or degree; less than normal in degree, intensity or amount.: An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Infectious Disorder","conceptCode":"C26726","definition":"A disorder resulting from the presence and activity of a microbial, viral, fungal, or parasitic agent. It can be transmitted by direct or indirect contact.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Low","conceptCode":"C54722","definition":"A minimum level or position or degree; less than normal in degree, intensity or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"IgG","conceptCode":"C568","definition":"An immunoglobulin isotype (subclass) that characterizes secondary immune responses.  This isotype is further broken down into several smaller subclasses (IgG1, IgG2a, IgG2b, IgG3 in the mouse; IgG1-4 in the human), and each subclass is differentially synthesized and secreted into the serum upon differential immune stimuli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2AB6F752-784B-C33D-E050-BB89AD432626","latestVersionIndicator":"Yes","beginDate":"2016-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2AB6F752-7864-C33D-E050-BB89AD432626","beginDate":"2016-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-01","modifiedBy":"ONEDATA","dateModified":"2016-02-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5116271","version":"1","preferredName":"Intravenous Immunoglobulin Therapy Reason","preferredDefinition":"The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections.:An explanation of the cause of some phenomenon or action.","longName":"C121331:C25638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Immunoglobulin Therapy","conceptCode":"C121331","definition":"The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2AB6F752-77C4-C33D-E050-BB89AD432626","latestVersionIndicator":"Yes","beginDate":"2016-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-01","modifiedBy":"ONEDATA","dateModified":"2016-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2AB6F752-77D5-C33D-E050-BB89AD432626","latestVersionIndicator":"Yes","beginDate":"2016-02-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-01","modifiedBy":"NYCHM","dateModified":"2017-01-31","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"HPST_IR_ivig_admin_rsn","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Specify the indication for which IVIG was given","type":"Alternate Question Text","description":"Specify the indication for which IVIG was given","url":null,"context":"NHLBI"},{"name":"Specify the indication for which IVIG was given","type":"Application Standard Question Text","description":"Specify the indication for which IVIG was given","url":null,"context":"NHLBI"},{"name":"What was the reason for intra","type":"Preferred Question Text","description":"What was the reason for intravenous immunoglobulin therapy?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2668C325-B22E-0F5F-E050-BB89AD436D58","latestVersionIndicator":"Yes","beginDate":"2015-12-08","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-12-08","modifiedBy":"NYCHM","dateModified":"2017-02-01","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}